EUFLEXXA (1% sodium hyaluronate)
Ferring Pharmaceuticals, Inc. · Decision date Sep 2, 2026
What did the FDA decide?
The FDA record for P010029/S043 lists a 30-day notice from Ferring Pharmaceuticals, Inc. for EUFLEXXA (1% sodium hyaluronate), categorized under the product code MOZ, device category "Acid, hyaluronic, intraarticular," and specialty Orthopedic. The reported statement is the introduction of a new Working Cell Bank designated "WC18-16072025." The stated supplement reason is "Process Change - Manufacturer/Sterilizer/Packager/Supplier."
The identifier P010029/S043 ties this notice to the original PMA P010029 as supplement S043. A 30-day notice of a manufacturing process change is not an original PMA approval, and the record supports no conclusion about safety, clinical effectiveness, or a new indication. The fields do not specify which manufacturing step the new bank affects, what characterization or testing was performed, or any acceptance criteria; those details are absent from the supplied data.
FDA approval order statement
introduction of a new Working Cell Bank (WCB) "WC18-16072025"
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Orthopedic
- Decision date
- Sep 2, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P010029/S043
- Regulatory pathway
- PMA supplement
- Applicant
- Ferring Pharmaceuticals, Inc.
- Product code
- MOZ
- Decision code
- OK30
- Decision date
- Sep 2, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Acid, hyaluronic, intraarticular.
- Applicant
- Ferring Pharmaceuticals, Inc.
- Product code
- MOZ
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P010029. Subsequent supplements may change the device or its indications.
FDA decision timeline
P010029 · Original PMA
EUFLEXXA (1% SODIUM HYALURONATE)
P010029/S042 · Related supplement
EUFLEXXA (1% SODIUM HYALURONATE)
P010029/S043 received
Application receipt date recorded by FDA.
P010029/S043 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P010029. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P010029
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Ferring Pharmaceuticals, Inc. | PMA approval | Dec 3, 2004 | FDA | |
EUFLEXXA (1% SODIUM HYALURONATE)P010029/S042 | Ferring Pharmaceuticals, Inc. | PMA supplement | Oct 16, 2025 | FDA |
Explore the linked device profile
Other records with product code MOZ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Gel-OneP080020/S056 | Seikagaku Corp. | PMA supplement | Sep 4, 2026 | FDA |
SUPARTZ FXP980044/S067 | Seikagaku Corp. | PMA supplement | Sep 4, 2026 | FDA |
Orthovisc Injectable Intra-Articular DevicesP030019/S028 | Anika Therapeutics, Inc. | PMA supplement | Aug 28, 2026 | FDA |
GEL-ONEP080020/S057 | Seikagaku Corp. | PMA supplement | Aug 26, 2026 | FDA |
SUPARTZ FXP980044/S068 | Seikagaku Corp. | PMA supplement | Aug 26, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Ferring Pharmaceuticals, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 100 Interpace Pkwy., Parsippany, NJ, 07054
Sources and methodology
- Original FDA record: P010029/S043
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


